Suscribirse

Antihypertensive and renal protective effect of Shunaoxin pill combined with captopril on spontaneous hypertension rats - 14/03/20

Doi : 10.1016/j.biopha.2020.109977 
Shuli Man a, , Li Yang a , Hao Xiang a , Guanyu Lu b , Yijia Wang d , Changxiao Liu e , Wenyuan Gao c,
a State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Microbiology, Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, National and Local United Engineering Lab of Metabolic Control Fermentation Technology, China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, 300457, China 
b State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Food Nutrition and Safety, Ministry of Education, College of Food Engineering and Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China 
c Tianjin Key Laboratory for Modern Drug Delivery and High Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, China 
d Tianjin International School, 4-1 Sishui Rd, Hexi District, Tianjin, 300222, China 
e The State Key Laboratories of Pharmacodynamics and Pharmacokinetics, Tianjin, 300193, China 

Corresponding author at: College of Biotechnology, Tianjin University of Science & Technology, TEDA 13th street, Tianjin, 300457, China.College of BiotechnologyTianjin University of Science & TechnologyTEDA 13th streetTianjin300457China⁎⁎Corresponding author at: School of Pharmaceutical Science and Technology, Tianjin University, Weijin Road, Tianjin, 300072, China.School of Pharmaceutical Science and TechnologyTianjin UniversityWeijin RoadTianjin300072China

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 8
Iconografías 6
Vídeos 0
Otros 0

Abstract

Introduction

According to previous reports, hypertension has become the most common chronic disease in the world. Captopril, an angiotensin-converting enzyme inhibitor, has been widely used for the therapy of arterial hypertension and cardiovascular diseases therapy. Besides, Shunaoxin pill (SNX) as a traditional Chinese prescription showed antihypertensive effect in our previous research.

Objective

This study means to investigate whether SNX combining with captopril could show antihypertensive and renal protective effects on spontaneous hypertension rats (SHRs).

Methods

SHRs were randomly assigned to four treatment groups, including non-treated group, captopril, SNX, and captopril + SNX-treated groups. Their body weight and systolic blood pressure (SBP) were measured weekly. Histopathological examination was analyzed through Masson staining and hematoxylin and eosin staining. Biochemical analyses, ELISA, and western blot were used to analyze their combining mechanism.

Results

In this experiment, this combinatorial therapy significantly reduced aortic wall thickness, increased the content of NO, NOS and eNOS, decreased the content of bradykinin and endothelin 1(ET-1), and regulated the levels of TG, TC and HDLC back to normal, which suggested they could induce vasodilation and lower blood pressure. Meanwhile, histological examination alleviated that captopril + SNX remarkably inhibited renal injury, including tubular disorder, inflammatory cell infiltration and fibrosis. They down-regulated the serum levels of BUN and Cr, protein expression of IL-1β, NF-κB, Bax, Cyt c, caspase 3, 8 and 9 in kidney tissues and significantly increased the levels of Bcl-2 in kidney tissues compared with monotherapy group.

Conclusion

The combinatorial treatment of SNX and captopril lowered blood pressure through adjusting NO/NOS, ET-1 and dyslipidemia profile. Furthermore, this treatment alleviated the kidney damage via reducing the release of inflammatory factors and the expression of apoptotic markers. Therefore, these results provided a rationale for future clinical use of SNX combined with captopril in antihypertensive and protecting renal functions in hypertension.

El texto completo de este artículo está disponible en PDF.

Abbreviations : Ang II, BUN, cGMP, Cr, Cyt c, eNOS, ET-1, HDLC, HE, IL, LDLC, NF-κB, SBP, SHR, TC, TG, TNF-α, TNOS, TUNEL, WKY

Keywords : Shunaoxin pill, Captopril, Combinatorial treatment, Antihypertension, Renoprotection


Esquema


© 2020  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 125

Artículo 109977- mai 2020 Regresar al número
Artículo precedente Artículo precedente
  • Investigation of protective effects of apilarnil against lipopolysaccharide induced liver injury in rats via TLR 4/ HMGB-1/ NF-κB pathway
  • Züleyha Doğanyiğit, Aslı Okan, Emin Kaymak, Dilek Pandır, Sibel Silici
| Artículo siguiente Artículo siguiente
  • Differential expression of lncRNAs during silicosis and the role of LOC103691771 in myofibroblast differentiation induced by TGF-β1
  • Wenchen Cai, Hong Xu, Bonan Zhang, Xuemin Gao, Shumin Li, Zhongqiu Wei, Shifeng Li, Na Mao, Fuyu Jin, Yaqian Li, Heliang Liu, Fang Yang

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.